eisai

Total Investment of Approx. USD 8.5 Million in Malaria and NTD R&D Projects With Partners Including MMV, GSK, Tanabe Pharma, Eisai and DNDi

TOKYO, April 22, 2026 /PRNewswire/ -- The Global Health Innovative Technology (GHIT) Fund announced today a total investment of approximately JPY…

5 days ago

Total Investment of Approx. USD 8.8 Million in Malaria, Tuberculosis, and NTD R&D Projects with Partners Including Mahidol University, Barcelona Institute for Global Health, and Eisai

TOKYO, Feb. 3, 2026 /PRNewswire/ -- The Global Health Innovative Technology (GHIT) Fund announced today a total investment of approximately JPY…

3 months ago

Eisai Initiated Rolling Supplemental Biologics License Application to the U.S. FDA for LEQEMBI IQLIK(lecanemab-irmb) as a Subcutaneous Starting Dose for the Treatment of Early Alzheimers Disease Under Fast Track Status

LEQEMBI IQLIK, if approved for initiation dosing, would be the first and only anti-amyloid treatment to offer at-home injection from…

8 months ago